Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Assessment of Prescribed Class of Anxiolytics and Antidepressants - In Terms of Efficacy, Quality of Life and Cost Analysis in a Tertiary Care Hospital


Affiliations
1 KMCH College of Pharmacy, Dep. of Pharmacy Practice, Coimbtore, Tamil Nadu-641014, India
2 Mallige College of Pharmacy, Bangalore-5620090, India
3 KMCH college of Pharmacy, Dep. of Pharmacy Practice, Coimbtore, Tamil Nadu-641014, India
     

   Subscribe/Renew Journal


Though the non-pharmacological treatment play a key role in anxious and depressive patients the drugs like antidepressants and anxiolytics have an elegant role in treating these patients. The success rates with newly diagnosed patients were better. Drugs are necessary to reduce the risk of developing chronic conditions. We have assessed the efficacy of anxiolytics and antidepressants prescribed (to newly diagnosed patients), cost of medications, quality of life in a Multi Specialty Hospital. An assessment was made in newly diagnosed patients with anxiety and depression to study the efficacy of antidepressants and anxiolytics prescribed to them, and their quality of life. Also, the total cost incurred by the patients for one month after diagnoses were evaluated. 100 patients were included in this study, conducted over a period of 6 months. The study sample consisted of 61 females and 39 males. Patients were treated with both single and two drug therapy. There was a significant difference in both the therapy. With the mean differences in both the therapy groups, single drug therapy itself is effective for treating the newly diagnosed patients. All the drugs prescribed significantly improved the health condition of anxiety and depressive patients. In single drug therapy Escitalopram is considered as the drug that has more efficacies with respect to the mean values. Same way in two drug therapy the combination of Escitalopram+Alprazolam is more effective with respect to the mean values. Regarding the cost analysis, Escitalopram is the costliest drug. Though the quality of life of the patients shows significant improvement, it can be improved much more through patient awareness programs and patient education.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Lloyd G.G, Sharpe M. C, Medical psychiatry, Davidson's Principles and Practice of Medicine, 19th edition, Churchill Livingstone, 2002; 245-247.

  • Garyson S. Norquist and Darrel A. Regier, The Epidemiology of Psychiatric Disorders and the De Facto Mental Health Care System, Annual Review of Medicine, 1996; 47: 473-479.

  • Victor.I. Reus Psychiatric Disorders, In: Eugene Braunwald, Anthony. S.Fauci, Dennis L. Kaspar, Stephen. L.Hauser, Dan.L.Longo, J.Larry Jameson, Editors. Harrison's Principles of Internal Medicine, 15th edition. New York: Mc Graw-Hill, 2001; 2542.

  • Mark H. Beers and Robert Berkow, The Merck Manual of Diagnosis and therapy, 17th edition, Merck research Laboratories (USA), 1999; 1564.

  • Adrienne Z. Ables, Otis L. Baughman, Antidepressants: Update on New Agents and Indications, Am Fam Physician, 2003; 67: 547-554

  • Dahl AA, Grov EK, Moum T, Fossa SD, Anxiety Depression and Quality of Life in caregivers of patients with cancer in late palliative phase, Annals of Oncology, 2005; 16: 1185- 1191

  • Pathiyil Ravi Shankar, Samit Roy, Patterns of Prescription And Drug use in a Psychiatry outpatient Department in a teaching hospital in western Nepal, The Internet journal of Pharmacology, 2002;1-8.

  • Donoghue, Timothy R. Hylan, Antidepressants use in the Clinical Practice Efficacy vs Effectiveness, 2001; 179: s9- s17.

  • Dan J. Stein, Elisabeth Wreford Anderson, Malcolm Lader, Escitalopram versus Paroxetine for social anxiety disorder: Analysis of Efficacy for different symptom dimensions, European Neuropsychopharmacology, 2006; 16: 33-38.

  • Jack M. Gorman, Justine M. Kent, Jeremy D. Coplan, Current and Emerging Therapeutics of Anxiety and Stress Disorders, American College of Neuropsychopharmacology, 2002; 5: 967-980.

  • Brian C. Lund, Michael Flaum, Laura A. Adam, Paul J. Perry, Psychiatric Prescribing Trends and Practices in Iowa's Prisons, Psychiatric services, 2002; 53: 1023-1024.

  • Jain-ping Chen, Charles Barron, Keh-Ming Lin, Henry Chung, Prescribing medication for Asians with mental disorder, west J med, 176; 2002: 271-275

  • Helena S. Johnson, Heidi M. Inderbitzen-Nolan, Ann M. Schapman, A comparison between socially anxious and depressive symptomatology in youth: a focus on perceived family environment, Anxiety Disorders, 2005; 19: 423-442.

  • Niclo Csacaleda, Jean-Philip Boulenger, Pharmacologic Treatment Effective in both Generalized Anxiety Disorder and Major Depressive Disorder: Clinical and Theoretical implications, Can J Psychiatry, 1998; 43: 722-730


Abstract Views: 308

PDF Views: 1




  • Assessment of Prescribed Class of Anxiolytics and Antidepressants - In Terms of Efficacy, Quality of Life and Cost Analysis in a Tertiary Care Hospital

Abstract Views: 308  |  PDF Views: 1

Authors

R. Kingston
KMCH College of Pharmacy, Dep. of Pharmacy Practice, Coimbtore, Tamil Nadu-641014, India
Shivakumar Swamy
Mallige College of Pharmacy, Bangalore-5620090, India
Arihara Sivakumar
KMCH college of Pharmacy, Dep. of Pharmacy Practice, Coimbtore, Tamil Nadu-641014, India

Abstract


Though the non-pharmacological treatment play a key role in anxious and depressive patients the drugs like antidepressants and anxiolytics have an elegant role in treating these patients. The success rates with newly diagnosed patients were better. Drugs are necessary to reduce the risk of developing chronic conditions. We have assessed the efficacy of anxiolytics and antidepressants prescribed (to newly diagnosed patients), cost of medications, quality of life in a Multi Specialty Hospital. An assessment was made in newly diagnosed patients with anxiety and depression to study the efficacy of antidepressants and anxiolytics prescribed to them, and their quality of life. Also, the total cost incurred by the patients for one month after diagnoses were evaluated. 100 patients were included in this study, conducted over a period of 6 months. The study sample consisted of 61 females and 39 males. Patients were treated with both single and two drug therapy. There was a significant difference in both the therapy. With the mean differences in both the therapy groups, single drug therapy itself is effective for treating the newly diagnosed patients. All the drugs prescribed significantly improved the health condition of anxiety and depressive patients. In single drug therapy Escitalopram is considered as the drug that has more efficacies with respect to the mean values. Same way in two drug therapy the combination of Escitalopram+Alprazolam is more effective with respect to the mean values. Regarding the cost analysis, Escitalopram is the costliest drug. Though the quality of life of the patients shows significant improvement, it can be improved much more through patient awareness programs and patient education.

References